Researchers uncover mechanisms leading to portal hypertension

September 29, 2005

DALLAS - Sept. 29, 2005 - A physician-scientist at UT Southwestern Medical Center and his research team have identified mechanisms causing a potentially deadly type of hypertension that results from liver damage - findings that could lead to its prevention.

This particular type of hypertension, called portal hypertension, affects the blood flow into the portal vein, which feeds blood to the liver.

Dr. Don Rockey, the new chief of the digestive and liver diseases at UT Southwestern, identified the cellular activity that results in portal hypertension. He and his colleagues then took the research a step further, showing that if the process can be interrupted, the hypertension subsides.

The National Institutes of Health-funded research - available online and scheduled to appear in a future issue of the journal Nature Medicine - was conducted by Dr. Rockey while he was at Duke University Medical Center.

"Portal hypertension is a deadly disease that complicates many forms of chronic liver injury," Dr. Rockey said. "When this occurs, in its most severe form, the prognosis definitely becomes guarded," often leading to the need for a liver transplant.

The short-term mortality for patients with portal hypertension is about 30 percent. The latest research opens new ground scientifically and has implications for possible clinical approaches, said Dr. Rockey.

"The end result of portal hypertension is bleeding and development of ascites [fluid in the abdomen]; so if you could treat it early, you could prevent bleeding and/or the formation of ascites," he said.

Portal hypertension is similar to the widely known essential hypertension, which impairs blood flow to the heart systems. But portal hypertension affects blood flow to the liver-related systems.

The liver is an essential organ that washes the body's blood of wastes and poisons. Cirrhosis of the liver occurs when the cells are damaged. Scarring often results, reducing blood flow into the liver and raising pressure on veins not designed to handle that much blood flow. The high pressure can cause veins to burst, resulting in internal bleeding and potentially death.

Previous studies have shown that, at the cellular level, portal hypertension results from reduced production of needed nitric oxide, which regulates expansion of the blood vessels.

Dr. Rockey's research identified how the nitric oxide production breaks down due to the effects of the protein GRK2. The protein attaches to another protein called AKT, interrupting the creation of nitric oxide.

"We've shown that the endothelial cells that line the blood vessels in the liver don't work quite right. Specifically, they don't produce nitric oxide," Dr. Rockey said. "The problem is that there are a number of signaling pathways that are disrupted and that results in the reduced production of nitric oxide."

In addition to identifying how the system breaks down, Dr. Rockey's study showed that reducing the GRK2 production restored AKT production, allowing nitric oxide levels to stabilize and blood pressure to return to normal.

Further research will be needed, Dr. Rockey said, to determine how to control GRK2 proteins that interfere with AKT or ways to bolster AKT protein production to maintain nitric oxide production.
-end-
This news release is available on our World Wide Web home page at http://www.utsouthwestern.edu/home/news/index.html

To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews

UT Southwestern Medical Center

Related Hypertension Articles from Brightsurf:

Risk of target organ damage in patients with masked hypertension versus sustained hypertension
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.1261, Yue Wu, Guoyue Zhang, Rong Hu and Jianlin Du from The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the risk of target organ damage in patients with masked hypertension versus sustained hypertension.

Overactive enzyme causes hereditary hypertension
After more than 40 years, several teams at the MDC and ECRC have now made a breakthrough discovery with the help of two animal models: they have proven that an altered gene encoding the enzyme PDE3A causes an inherited form of high blood pressure.

Diagnosing hypertension in children
Study results call into question the utility of testing blood pressure load--the proportion of elevated blood pressure readings detected over 24 hours--for diagnosing hypertension in children.

When the best treatment for hypertension is to wait
A new study concluded that a physician's decision not to intensify hypertension treatment is often a contextually appropriate choice.

Treatment of hypertension induced albuminuria
Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria.

Diagnosing and treating resistant hypertension
Resistant blood pressure affects 12 percent to 15 percent of people currently being treated for high blood pressure.

Dementia can be caused by hypertension
A new study in Cardiovascular Research indicates that patients with high blood pressure are at a higher risk of developing dementia.

Hormone imbalance causes treatment-resistant hypertension
British researchers have discovered a hormone imbalance that explains why it is very difficult to control blood pressure in around 10 per cent of hypertension patients.

Breastfeeding reduces hypertension risk
A study published in the American Journal of Hypertension indicates that women who breastfeed more children, and for longer periods of time, are less likely to suffer from hypertension after they reach menopause.

Lung cancer triggers pulmonary hypertension
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.

Read More: Hypertension News and Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.